# Healiva acquires cell therapy manufacturing assets from B. Braun

Healiva announced the acquisition of critical manufacturing assets, including a qualified cell bank, from B. Braun Medical AG Switzerland to accelerate the launch of its EpiDex cell therapy.

- Type: Acquisition
- Announced: 2022-11-21
- Where: Lugano, Switzerland, Switzerland
- Status: completed
- Products: cell therapy manufacturing assets, EpiDex cell therapy
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Healiva](https://endata.com/companies/66782.md) (acquirer)
- [B. Braun Medical AG Switzerland](https://endata.com/companies/66783.md) (target)

## Sources

- [biospace.com](https://www.biospace.com/healiva-acquires-critical-cell-therapy-manufacturing-assets-from-b-braun), 2022-11-21: "This transaction will enable Healiva to accelerate the launch of EpiDex, which is projected for Q4 2023."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.